

Stock Index Performance					
Index	Week	YTD	12-mo.	2012	5-yr.
Dow Jones Industrial Avg. (13,435)	3.87%	2.56%	11.19%	10.24%	3.87%
S&P 500 (1,466)	4.59%	2.84%	17.43%	16.00%	3.04%
NASDAQ 100 (2,724)	4.53%	2.39%	18.46%	18.35%	7.69%
S&P 500 Growth	4.40%	2.57%	16.18%	14.71%	4.74%
S&P 500 Value	4.78%	3.14%	19.12%	17.77%	1.32%
S&P MidCap 400 Growth	5.14%	3.38%	21.21%	17.62%	7.67%
S&P MidCap 400 Value	5.18%	3.63%	22.00%	19.10%	6.38%
S&P SmallCap 600 Growth	5.41%	3.29%	18.89%	15.27%	7.46%
S&P SmallCap 600 Value	5.39%	3.46%	21.12%	18.88%	6.97%
MSCI EAFE	1.71%	1.82%	17.18%	17.32%	-2.95%
MSCI World (ex US)	1.91%	1.91%	16.62%	16.83%	-2.15%
MSCI World	3.27%	2.37%	16.49%	15.83%	-0.14%
MSCI Emerging Markets	2.16%	2.16%	18.02%	18.22%	-0.17%

Source: Bloomberg. Returns are total returns. The 5-yr. return is an average annual. One-week, YTD, 12-mo. and 5-yr. performance returns calculated through 1/4/13.

S&P Sector Performance					
Index	Week	YTD	12-mo.	2012	5-yr.
Consumer Discretionary	4.79%	2.73%	25.44%	24.14%	11.63%
Consumer Staples	3.80%	2.67%	14.22%	11.08%	8.06%
Energy	5.47%	3.30%	5.20%	4.64%	0.52%
Financials	5.52%	4.07%	31.15%	28.92%	-7.01%
Health Care	3.72%	2.48%	19.75%	17.89%	5.57%
Industrials	4.98%	3.05%	15.95%	15.42%	2.48%
Information Technology	4.02%	1.82%	14.65%	14.82%	5.39%
Materials	4.97%	2.89%	14.45%	15.24%	1.59%
Telecom Services	4.73%	3.55%	23.11%	18.31%	3.75%
Utilities	3.79%	2.37%	6.08%	1.31%	0.98%

Source: Bloomberg. Returns are total returns. The 5-yr. return is an average annual. One-week, YTD, 12-mo. and 5-yr. performance returns calculated through 1/4/13.

Bond Index Performance					
Index	Week	YTD	12-mo.	2012	5-yr.
U.S. Treasury: Intermediate	-0.39%	-0.37%	1.58%	1.71%	4.33%
GNMA 30 Year	-0.18%	-0.23%	2.17%	2.44%	5.83%
U.S. Aggregate	-0.53%	-0.43%	4.06%	4.21%	5.66%
U.S. Corporate High Yield	0.73%	0.71%	15.89%	15.81%	10.64%
U.S. Corporate Investment Grade	-0.74%	-0.46%	9.72%	9.82%	7.56%
Municipal Bond: Long Bond (22+)	-0.18%	-0.20%	10.88%	11.26%	6.09%
Global Aggregate	-1.28%	-1.14%	3.42%	4.32%	4.86%

Source: Barclays Capital. Returns are total returns. The 5-yr. return is an average annual. One-week, YTD, 12-mo. and 5-yr. performance returns calculated through 1/4/13.

Key Rates			
As of 1/4/13			
Fed Funds	0.00-0.25%	5-yr CD	1.35%
LIBOR (1-month)	0.21%	2-yr T-Note	0.27%
CPI - Headline	1.80%	5-yr T-Note	0.81%
CPI - Core	1.90%	10-yr T-Note	1.90%
Money Market Accts.	0.50%	30-yr T-Bond	3.10%
Money Market Funds	0.02%	30-yr Mortgage	3.54%
6-mo CD	0.47%	Prime Rate	3.25%
1-yr CD	0.71%	Bond Buyer 40	4.10%

Sources: Bankrate.com, iMoneyNet.com and Bloomberg.

Market Indicators	
As of 1/4/13	
TED Spread	24 bps
Investment Grade Spread (A2)	167 bps
ML High Yield Master II Index Spread	504 bps

Sources: Bloomberg and Merrill Lynch via Bloomberg.

Weekly Fund Flows				
Estimated Flows to Long-Term Mutual Funds for the Week Ended 12/26/12				
	Current Week		Previous	
Domestic Equity	-\$3.637	Billion	-\$5.224	Billion
Foreign Equity	\$363	Million	\$292	Million
Taxable Bond	\$3.141	Billion	\$3.694	Billion
Municipal Bond	-\$685	Million	\$3.263	Billion

  

Change in Money Market Fund Assets for the Week Ended 1/2/13				
	Current Week		Previous	
Retail	\$13.89	Billion	\$9.45	Billion
Institutional	\$23.89	Billion	\$18.93	Billion

Source: Investment Company Institute

Factoids for the week of December 31, 2012 – January 4, 2013
<p><b>Monday, December 31, 2012</b></p> <p>S&amp;P 500 stock buybacks totaled \$103.7 billion in Q3'12, down 7.2% from the \$111.7 billion executed in Q2'12, according to Standard &amp; Poor's. Buybacks totaled \$118.4 billion in Q3'11. S&amp;P 500 buyback totals have topped \$100 billion in four of the past six quarters. The highest quarterly total since the end of 2006 was the \$172.0 billion executed in Q3'07. The two most active sectors in Q3'12 were Health Care (\$21.8 billion) and Information Technology (\$18.0 billion). In the first nine months of 2012, S&amp;P 500 buybacks totaled \$299.8, while dividend payouts totaled \$201.2 billion.</p>
<p><b>Tuesday, January 1, 2013</b></p> <p>Markets Closed – New Year's Day Holiday.</p>
<p><b>Wednesday, January 2, 2013</b></p> <p>In December, the dividend-payers (403) in the S&amp;P 500 (equal weight) posted a total return of 2.08%, vs. 3.44% for the non-payers (97), according to Standard &amp; Poor's. In 2012, the payers were up 16.14%, vs. a gain of 19.20% for the non-payers. The number of dividend increases in 2012 totaled 333, up from 320 increases in 2011. Fifteen companies initiated dividends, down from 22 a year ago. Eleven dividends were cut, up from five cuts a year ago.</p>
<p><b>Thursday, January 3, 2013</b></p> <p>The S&amp;P 500 did not post a single closing price value in 2012 that was below its 2011 year-end close of 1257.60, according to Bespoke Investment Group. In other words, the index was up, on a year-to-date basis, every trading day of 2012. Since 1928, only eight other calendar years (1943, 1951, 1958, 1964, 1967, 1975, 1976 &amp; 1979) accomplished this feat. The S&amp;P 500's average price-only return for these nine years (including 2012) was 20.37%, according to Bespoke. The index was up 13.41% (price-only) in 2012. With respect to the previous eight occasions, the average price-only return for the following year was 10.52%. The S&amp;P 500 was up 2.54% its first trading day of 2013.</p>
<p><b>Friday, January 4, 2013</b></p> <p>The U.S. Food and Drug Administration (FDA) approved 39 new molecular entities in 2012, the most in 16 years, according to FierceBiotech.com. From 2000-2009, an average of 24 new drugs per year garnered the approval of the FDA. The average was 31 in the 1990s. Analysts at McKinsey see the FDA approving 35 new drugs per year through 2016. Some industry analysts believe we are embarking on a new era of productivity for biopharma R&amp;D. The new medicines should help bolster sales for branded drugs in the face of hefty patent expirations. EvaluatePharma estimates that \$290 billion in branded drug sales are at risk from patent expirations between 2012 and 2018.</p>